medwireNews: Japanese researchers say that a fecal occult blood test could help screen for treatment-induced hemorrhagic colitis in chronic myeloid leukemia (CML) patients taking dasatinib.
They believe it could be "a useful, non-invasive screening test", with the diagnosis confirmed by colonoscopy and pathologic analysis.
Among 30 CML patients who had received a tyrosine kinase inhibitor for at least 1 month - nilotinib in five patients, imatinib in seven, and dasatinib in 18 - 10 had a positive fecal occult blood test. All 10 patients had received dasatinib, and none exhibited clinically relevant symptoms.
https://www.medwiren...uced-h/11954346
